Organogenesis Holdings Inc. Sustainability Profile
Organogenesis Holdings Inc., a leading player in the regenerative medicine sector, is headquartered in the United States. Founded in 1985, the company has established itself as a pioneer in advanced wound care and surgical biologics, focusing on innovative solutions that enhance healing and improve patient outcomes. With a strong presence across North America, Organogenesis offers a diverse portfolio of products, including allograft and xenograft tissue products, which are distinguished by their unique biological properties and effectiveness. The company has achieved significant milestones, including FDA approvals for several of its key offerings, solidifying its position in the market. Recognised for its commitment to quality and innovation, Organogenesis continues to lead the way in transforming patient care through its cutting-edge therapies and comprehensive support services.
DitchCarbon Score
How does Organogenesis Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organogenesis Holdings Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organogenesis Holdings Inc.'s reported carbon emissions
Organogenesis Holdings Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Organogenesis may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As a result, the company's climate commitments and emissions management strategies remain unclear within the current industry context.
How Carbon Intensive is Organogenesis Holdings Inc.'s Industry?
How Carbon Intensive is Organogenesis Holdings Inc.'s Location?
Organogenesis Holdings Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Organogenesis Holdings Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
